Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

INFORMED CONSENT REGS NEED REWRITE TO CREATE ONE STANDARD OF INCREMENTAL RISK, NIH/FDA TOLD; IRBs SHOULD GET MORE LEEWAY TO WAIVE INFORMED CONSENT

Executive Summary

Informed consent documents should be rewritten by the federal government to create a uniform standard allowing Institutional Review Boards to assess risk-benefit using a standard of situational incremental risk, Carolinas Medical Center Research Services Director Beth Ribbeck asserted at a joint FDA/National Institutes of Health conference on informed consent in emergency research Jan. 9-10 in Bethesda, Md.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS025628

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel